President & COO of Xeris Biopharma Holdings Kevin McCulloch Buys 1.5% More Shares

Potential Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) shareholders may wish to note that the President & COO, Kevin McCulloch, recently bought US$109k worth of stock, paying US$4.38 for each share. Although the purchase only increased their holding by 1.5%, it is still a solid purchase in our view.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

The Last 12 Months Of Insider Transactions At Xeris Biopharma Holdings

Over the last year, we can see that the biggest insider sale was by the Chief Legal Officer & Corporate Secretary, Beth Hecht, for US$217k worth of shares, at about US$5.43 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$4.58. So it may not shed much light on insider confidence at current levels. Beth Hecht was the only individual insider to sell over the last year.

Over the last year, we can see that insiders have bought 33.80k shares worth US$130k. But insiders sold 40.00k shares worth US$217k. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

Check out our latest analysis for Xeris Biopharma Holdings

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

Insider Ownership

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. It appears that Xeris Biopharma Holdings insiders own 4.6% of the company, worth about US$33m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Does This Data Suggest About Xeris Biopharma Holdings Insiders?

Unfortunately, there has been more insider selling of Xeris Biopharma Holdings stock, than buying, in the last three months. Zooming out, the longer term picture doesn't give us much comfort. While insiders do own shares, they don't own a heap, and they have been selling. We're in no rush to buy! While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To that end, you should learn about the 2 warning signs we've spotted with Xeris Biopharma Holdings (including 1 which is concerning).

Of course Xeris Biopharma Holdings may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.